Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Axsome Therapeutics, Inc. (NASDAQ: AXSM).

Full DD Report for AXSM

You must become a subscriber to view this report.


Recent News from (NASDAQ: AXSM)

Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27
Axsome Therapeutics' (AXSM) CEO Herriot Tabuteau on Q1 2018 Results - Earnings Call Transcript
Axsome Therapeutics (AXSM) Q1 2018 Earnings Conference Call May 08, 2018, 08:00 ET Executives Mark Jacobson - SVP, Operations Herriot Tabuteau - CEO Cedric O’Gorman - SVP, Clinical Development and Medical Affairs Analysts Matt Kaplan - Ladenburg Thalmann Bert Hazle...
Source: SeekingAlpha
Date: May, 08 2018 12:34
Axsome Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
NEW YORK, May 08, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2018...
Source: GlobeNewswire
Date: May, 08 2018 07:00
Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced a poster presentation on AXS-05 (bupropion and dextromethor...
Source: GlobeNewswire
Date: May, 03 2018 07:00
Axsome Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
Axsome to host conference call and webcast on Tuesday, May 8, 2018 at 8:00 AM Eastern Time NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous syst...
Source: GlobeNewswire
Date: May, 01 2018 07:00
Week 18 Breakout Forecast: Short-Term Picks To Give You An Edge
Breakout Forecast Selections for Week 18: Market conditions continue with extreme volatility. The positive momentum gauge spent a first full week in yellow (medium) that we have seen in a couple months, moving from a value of 54 last week to a value of 52 this week. The all time low for the ...
Source: SeekingAlpha
Date: April, 30 2018 14:11
3 Things In Biotech, April 28: Fighting Mental Disorders, And A New Strategy For Bacteria?
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated...
Source: SeekingAlpha
Date: April, 29 2018 08:00
Midday Gainers / Losers (04/26/2018)
Gainers: GNPX +81% . CRK +47% . VTVT +26% . CMG +24% . CCM +24% . MATR +22% . HZO +22% . UCTT +19% . PCMI +18% . AXSM +17% . More news on: Genprex, Inc, Comstock Resources Inc., vTv Therapeutics, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 26 2018 12:40
Premarket Gainers as of 9:05 am (04/26/2018)
CRK +50% . More news on: Comstock Resources Inc., Mattersight Corporation, Penn National Gaming, Inc., Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: April, 26 2018 09:23
Axsome's late-stage study of AXS-05 in treatment-resistant depression to continue; shares up 13% premarket
Thinly traded nano cap Axsome Therapeutics (NASDAQ: AXSM ) is up  13%  premarket on light volume on the heels of its announcement that its Phase 3 clinical trial, STRIDE-1, assessing Fast Track-tagged AXS-05 in treatment resistant depression will continue as planned. The decision...
Source: SeekingAlpha
Date: April, 26 2018 08:34

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-183.503.503.553.4571,670
2018-05-173.503.503.553.4571,670
2017-06-204.605.105.304.60929,126
2017-06-194.104.604.68534.05542,603
2017-06-163.954.104.103.95203,227

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-2012,74728,94744.0357Short
2018-08-179,15046,87719.5192Cover
2018-08-162,2168,72625.3954Cover
2018-08-151,50019,6597.6301Cover
2018-08-146026,4029.4033Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AXSM.


About Axsome Therapeutics, Inc. (NASDAQ: AXSM)

Logo for Axsome Therapeutics, Inc. (NASDAQ: AXSM)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $87,950,822 - 05/11/2018
  • Issue and Outstanding: 25,492,992 - 03/02/2018

 


Recent Filings from (NASDAQ: AXSM)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: April, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 07 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 26 2018

 

 


Daily Technical Chart for (NASDAQ: AXSM)

Daily Technical Chart for (NASDAQ: AXSM)


Stay tuned for daily updates and more on (NASDAQ: AXSM)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AXSM)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AXSM is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AXSM and does not buy, sell, or trade any shares of AXSM. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/